Cargando…

Efficacy of cenobamate for uncontrolled focal seizures: Post hoc analysis of a Phase 3, multicenter, open‐label study

OBJECTIVE: To report long‐term post hoc efficacy and safety data from 10 US study sites from an open‐label Phase 3 study of adjunctive cenobamate (NCT02535091). METHODS: Patients with uncontrolled focal seizures taking stable doses of 1–3 antiseizure medications (ASMs) were administered increasing d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sperling, Michael R., Abou‐Khalil, Bassel, Aboumatar, Sami, Bhatia, Perminder, Biton, Victor, Klein, Pavel, Krauss, Gregory L., Vossler, David G., Wechsler, Robert, Ferrari, Louis, Grall, Mindy, Rosenfeld, William E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Full‐length Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293007/ https://www.ncbi.nlm.nih.gov/pubmed/34633084 http://dx.doi.org/10.1111/epi.17091

Ejemplares similares

Post hoc analysis of a phase 3, multicenter, open‐label study of cenobamate for treatment of uncontrolled focal seizures: Effects of dose adjustments of concomitant antiseizure medications
por: Rosenfeld, William E., et al.
Publicado: (2021)

Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open‐label safety study
por: Sperling, Michael R., et al.
Publicado: (2020)

Long‐term safety of adjunctive cenobamate in patients with uncontrolled focal seizures: Open‐label extension of a randomized clinical study
por: French, Jacqueline A., et al.
Publicado: (2021)

Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures
por: Chung, Steve S., et al.
Publicado: (2020)

Long-term Efficacy and Safety From an Open-Label Extension of Adjunctive Cenobamate in Patients With Uncontrolled Focal Seizures
por: Klein, Pavel, et al.
Publicado: (2022)

Long‐term individual retention with cenobamate in adults with focal seizures: Pooled data from the clinical development program
por: Sander, Josemir W., et al.
Publicado: (2021)

Remarkably High Efficacy of Cenobamate in Adults With Focal-Onset Seizures: A Double-Blind, Randomized, Placebo-Controlled Trial
por: Vossler, David G.
Publicado: (2020)

Critical Appraisal of Cenobamate as Adjunctive Treatment of Focal Seizures in Adults
por: Zaccara, Gaetano, et al.
Publicado: (2021)

Cenobamate for treatment-resistant focal seizures: current evidence and place in therapy
por: Singh, Alok
Publicado: (2022)

Adjunctive Cenobamate for Focal-Onset Seizures in Adults: A Systematic Review and Meta-Analysis
por: Lattanzi, Simona, et al.
Publicado: (2020)

Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial
por: Sperling, Michael R, et al.
Publicado: (2015)

Effectiveness and safety of adjunctive cenobamate for focal seizures in adults with developmental disability treated in clinical practice
por: Connor, Gregory S., et al.
Publicado: (2022)

Real‐world safety and effectiveness of cenobamate in patients with focal onset seizures: Outcomes from an Expanded Access Program
por: Villanueva, Vicente, et al.
Publicado: (2023)

Anticonvulsant effects of cenobamate in chemically and electrically induced seizure models in rodents
por: Melnick, Susan M., et al.
Publicado: (2023)

Dose Adjustment of Concomitant Antiseizure Medications During Cenobamate Treatment: Expert Opinion Consensus Recommendations
por: Smith, Michael C., et al.
Publicado: (2022)

Onset of efficacy and adverse events during Cenobamate titration period
por: Steinhoff, Bernhard J., et al.
Publicado: (2022)

Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial‐onset seizures: A randomized historical‐control phase III study based in North America
por: Sperling, Michael R., et al.
Publicado: (2015)

Efficacy and safety of adjunctive perampanel in patients with focal seizures or generalized tonic‐clonic seizures: Post hoc analysis of Phase II and Phase III double‐blind and open‐label extension studies in India
por: Mehndiratta, Man M., et al.
Publicado: (2021)

Kv7 potassium channel activation with ICA-105665 reduces photoparoxysmal EEG responses in patients with epilepsy
por: Kasteleijn-Nolst Trenité, Dorotheé G A, et al.
Publicado: (2013)

Suppression of the photoparoxysmal response in photosensitive epilepsy with cenobamate (YKP3089)
por: Kasteleijn- Nolst Trenite, Dorothee G.A., et al.
Publicado: (2019)

Perampanel in real‐world clinical care of patients with epilepsy: Interim analysis of a phase IV study
por: Wheless, James, et al.
Publicado: (2020)

Evidence for long memory in focal seizure duration
por: Fan, Joline M., et al.
Publicado: (2021)

Efficacy and safety of adjunctive perampanel 4 mg/d for the treatment of focal seizures: A pooled post hoc analysis of four randomized, double‐blind, phase III studies
por: Steinhoff, Bernhard J., et al.
Publicado: (2020)

Novel seizure outcomes in patients with Lennox‐Gastaut syndrome: Post hoc analysis of seizure‐free days in rufinamide Study 303
por: Auvin, Stéphane, et al.
Publicado: (2019)

Is Cenobamate the Breakthrough We Have Been Wishing for?
por: Specchio, Nicola, et al.
Publicado: (2021)

Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study
por: Jacobson, Mercedes P, et al.
Publicado: (2015)

Impact of diagnostic delay on seizure outcome in newly diagnosed focal epilepsy
por: Parviainen, Laura, et al.
Publicado: (2020)

Cenobamate significantly improves seizure control in intellectually disabled patients with drug-resistant epilepsy and allows drug load reduction
por: Friedo, Anna-Lena, et al.
Publicado: (2023)

Real‐world experience with direct brain‐responsive neurostimulation for focal onset seizures
por: Razavi, Babak, et al.
Publicado: (2020)

Assessment of the long‐term efficacy and safety of adjunctive perampanel in tonic‐clonic seizures: Analysis of four open‐label extension studies
por: Rektor, Ivan, et al.
Publicado: (2020)

Cost-effectiveness of perampanel as an adjunctive treatment for uncontrolled focal seizures in pediatric patients: a Chinese perspective
por: Hu, Yani, et al.
Publicado: (2022)

An Ex Vivo Evaluation of Cenobamate Administered via Enteral Tubes
por: Ferrari, Louis, et al.
Publicado: (2020)

Real-World Experience Treating Pediatric Epilepsy Patients With Cenobamate
por: Makridis, Konstantin L., et al.
Publicado: (2022)

Cenobamate in refractory epilepsy: Overview of treatment options and practical considerations
por: Schmitz, Bettina, et al.
Publicado: (2023)

Understanding the burden of focal epilepsy as a function of seizure frequency in the United States, Europe, and Brazil
por: Gupta, Shaloo, et al.
Publicado: (2017)

Focal to bilateral tonic–clonic seizures are associated with widespread network abnormality in temporal lobe epilepsy
por: Sinha, Nishant, et al.
Publicado: (2021)

Final results from a Phase 3, long‐term, open‐label, repeat‐dose safety study of diazepam nasal spray for seizure clusters in patients with epilepsy
por: Wheless, James W., et al.
Publicado: (2021)

Seizure Susceptibility Prediction in Uncontrolled Epilepsy
por: Truong, Nhan Duy, et al.
Publicado: (2021)

Cenobamate (YKP3089) and Drug-Resistant Epilepsy: A Review of the Literature
por: Rissardo, Jamir Pitton, et al.
Publicado: (2023)

Open‐label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (4 to <12 years) with inadequately controlled focal seizures or generalized tonic‐clonic seizures
por: Fogarasi, Andras, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_263t5hc44ldqpl51o1ogdh0q6o